Two weeks ago, we reported that pembrolizumab worked well as first-line treatment for advanced lung cancer patients. Those benefits―which included a 40% reduction in risk of death compared to chemotherapy―led the FDA to grant Breakthrough Therapy Designation and Priority Review to the therapy.
Although the FDA had until December 24 to make a decision, U.S. regulators decided yesterday, two months ahead of schedule, to approve pembrolizumab (Keytruda ®, Merck) as a first-line option for patients with advanced non-small cell lung carcinoma (NSCLC). It’s important to note, however, that this approval is for patients whose tumors have high PD-L1 expression (more than half the cells expressed it) and don’t have any mutations in EGFR or ALK. Pembrolizumab is an anti-PD-1 checkpoint antibody that targets the PD-1/PD-L1 pathway and can help keep immune cells active against cancer.
Checkpoint Inhibitors Benefit Lung Cancer Patients in Clinical Trials
Read Previous Article
Pembrolizumab (Keytruda®) Approved as First-Line Option for Lung Cancer
Read Next Article
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Help us cheer on our Team CRI members who have been not only training for a marathon, but also helping to raise funds for a future immune to cancer.
This October for Liver Cancer Awareness Month, let’s delve into new treatments, research insights, and how we are fueling a future immune to liver cancer.